H.C. Wainwright raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $62 from $48 and keeps a Buy rating on the shares after the company announced FDA approval for mitapivat, marketed in the U.S. as Aqvesme. Following the approval, the firm has updated its model to shift the Aqvesme commercial launch in thalassemia from Q4 of 2025 to Q1 of 2026, consistent with management’s guidance, and now models Aqvesme pricing as $425,000 wholesale acquisition cost, compared to a previously estimated $335,000 WAC.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals price target raised to $38 from $32 at Truist
- Here’s Why Agios Stock (AGIO) Is Suddenly on the Rise Today
- Agios Pharmaceuticals’ Aqvesme to be introduced at $425K per patient per year
- Agios Pharmaceuticals price target raised to $34 from $32 at BofA
- FDA approves Agios Pharmaceuticals’ Aqvesme in anemia patients